IAEA Contribution to Nanosized Targeted Radiopharmaceuticals for Drug Delivery

Pharmaceutics

Irfan U. Khan¹  Blanca Ocampo-García²  Adriano Duatti³  Wanvimol Pasanphan⁴  Joao A. Osso⁵  Amir R. Jalilian⁵  Agnes Safrany⁵  Kattesh V. Katti⁶  Clelia Dispenza⁷  Piotr Ulański⁸  Ademar B. Lugao⁹  Laura Melendez-Alafort^1,10  Mariano Grasselli^1,11  Siti Mohd Janib^1,12  Michał Maurin^1,13  Hassan Yousefnia^1,14  Tamer M. Sakr^1,15  Say Chye Joachim Loo^1,16 

[1] Cyclotron and Allied Radiopharmaceutics Division, Institute of Nuclear Medicine and Oncology (INMOL), New Campus Road, Lahore 54600, Pakistan;Departamento de Materiales Radiactivos, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac 52750, Mexico;Department of Chemical and Pharmaceutical Sciences, University of Ferrara, 44121 Ferrara, Italy;Department of Materials Science, Faculty of Science, Kasetsart University, Bangkok 10900, Thailand;Department of Nuclear Sciences and Applications, International Atomic Energy Agency (IAEA), 1400 Vienna, Austria;Department of Radiology, Institute of Green Nanotechnology, School of Medicine, University of Missouri, University of Missouri Research Reactor (MURR), Medical School, One Hospital Drive, Columbia, MO 65212, USA;Dipartimento di Ingegneria, Università deli Studi di Palermo, 90133 Palermo, Italy;Institute of Applied Radiation Chemistry, Lodz University of Technology, 90-924 Łódź, Poland;Instituto de Pesquisas Energéticas e Nucleares, IPEN-CNEN, Av. Prof. Lineu Prestes, No. 2242, Cidade Universitária, São Paulo 05508-000, SP, Brazil;Istituto Oncologico Veneto IOV-IRCCS, Via Gattamelata 64, 35138 Padova, Italy;Laboratorio de Materiales Biotecnológicos (LaMaBio), Dpto de Ciencia y Tecnología, Universidad Nacional de Quilmes, Bernal 1876, Argentina;Medical Technology Division, Malaysian Nuclear Agency, Kajang 43000, Malaysia;National Centre for Nuclear Research, Radioisotope Centre POLATOM, 05-400 Otwock, Poland;Nuclear Science and Technology Research Institute (NSTRI), Tehran 11155-3486, Iran;Radioactive Isotopes and Generators Department, Hot Labs Center, Egyptian Atomic Energy Authority (EAEA), Cairo 13759, Egypt;School of Materials Science & Engineering (MSE), Spore Centre of Environmental Life Sciences Engineering (SCELSE), Lee Kong Chian School of Medicine, Harvard T.H. Chan School of Public Health, Nanyang Technological University (NTU), Singapore 639798, Singapore;

关键词: nanoparticles;    metallic;    non-metallic;    polymeric;    radiopharmaceuticals;    radioisotopes;   

DOI  :  10.3390/pharmaceutics14051060

来源: DOAJ

【 摘 要 】

The rapidly growing interest in the application of nanoscience in the future design of radiopharmaceuticals and the development of nanosized radiopharmaceuticals in the late 2000′s, resulted in the creation of a Coordinated Research Project (CRP) by the International Atomic Energy Agency (IAEA) in 2014. This CRP entitled ‘Nanosized delivery systems for radiopharmaceuticals’ involved a team of expert scientist from various member states. This team of scientists worked on a number of cutting-edge areas of nanoscience with a focus on developing well-defined, highly effective and site-specific delivery systems of radiopharmaceuticals. Specifically, focus areas of various teams of scientists comprised of the development of nanoparticles (NPs) based on metals, polymers, and gels, and their conjugation/encapsulation or decoration with various tumor avid ligands such as peptides, folates, and small molecule phytochemicals. The research and development efforts also comprised of developing optimum radiolabeling methods of various nano vectors using diagnostic and therapeutic radionuclides including Tc-99m, Ga-68, Lu-177 and Au-198. Concerted efforts of teams of scientists within this CRP has resulted in the development of various protocols and guidelines on delivery systems of nanoradiopharmaceuticals, training of numerous graduate students/post-doctoral fellows and publications in peer reviewed journals while establishing numerous productive scientific networks in various participating member states. Some of the innovative nanoconstructs were chosen for further preclinical applications—all aimed at ultimate clinical translation for treating human cancer patients. This review article summarizes outcomes of this major international scientific endeavor.

【 授权许可】

Unknown